Literature DB >> 17412283

Expression of programmed-death receptor ligands 1 and 2 may contribute to the poor stimulatory potential of murine immature dendritic cells.

Cheng Chen1, Qiu-Xia Qu, Jian-an Huang, Yi-Bei Zhu, Yan Ge, Qin Wang, Xue-Guang Zhang.   

Abstract

Recent data have revealed that Ag presentation by immature dendritic cells (imDCs) plays a role in establishing and maintaining T-cell tolerance, but the mechanism remains unclear. PD-L1 and PD-L2, ligands for programmed-death receptor 1 (PD-1), members of the expanding B7 family, were highlighted for their inhibitory role in T-cell responses. Here, we show that blockade of PD-1 ligands on imDCs resulted in enhanced T-cell proliferation, which is perhaps due to the enhancement of IL-2 production from DC-stimulated T cells. PD-1 ligands blockade on mDCs did not show a significant stimulatory effect as markedly as imDCs. The inhibitory effects of PD-1 ligands would be dependent on maturation status of DCs, where attenuated positive costimulatory molecules provided the opportunity for PD-1 ligands to exert their strong capacity. Our data are consistent with the hypothesis that imDCs have an inhibitory bias, and indicate that PD-L1 and PD-L2 contribute to the poor stimulatory capacity of imDCs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17412283     DOI: 10.1016/j.imbio.2007.01.004

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  12 in total

1.  Co-inhibitory molecules: Controlling the effectors or controlling the controllers?

Authors:  Govindarajan Thangavelu; Christa Smolarchuk; Colin C Anderson
Journal:  Self Nonself       Date:  2010-02-16

2.  Immunological markers predict the prognosis of patients with squamous non-small cell lung cancer.

Authors:  Long Jiang; Zerui Zhao; Shanshan Jiang; Yongbin Lin; Han Yang; Zehua Xie; Yaobin Lin; Hao Long
Journal:  Immunol Res       Date:  2015-07       Impact factor: 2.829

3.  High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation.

Authors:  Chuan-Yong Mu; Jian-An Huang; Ying Chen; Cheng Chen; Xue-Guang Zhang
Journal:  Med Oncol       Date:  2010-04-06       Impact factor: 3.064

4.  The role of co-inhibitory signals in spontaneous tolerance of weakly mismatched transplants.

Authors:  Govindarajan Thangavelu; Kenneth M Murphy; Hideo Yagita; Louis Boon; Colin C Anderson
Journal:  Immunobiology       Date:  2011-01-12       Impact factor: 3.144

5.  PD-1 ligand expression by human colonic myofibroblasts/fibroblasts regulates CD4+ T-cell activity.

Authors:  Irina V Pinchuk; Jamal I Saada; Ellen J Beswick; Gushyalatha Boya; Sumin M Qiu; Randy C Mifflin; Gottumukkala S Raju; Victor E Reyes; Don W Powell
Journal:  Gastroenterology       Date:  2008-07-17       Impact factor: 22.682

6.  Active systemic lupus erythematosus is associated with failure of antigen-presenting cells to express programmed death ligand-1.

Authors:  N Mozaffarian; A E Wiedeman; A M Stevens
Journal:  Rheumatology (Oxford)       Date:  2008-07-23       Impact factor: 7.580

7.  Role of biphasic changes in splenic dendritic cell activity in a mouse model of multiple organ dysfunction syndrome.

Authors:  Yi Lv; Qian Liu; Min Zhao; Yiduo Jin; Jiangyang Lu
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

Review 8.  The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion.

Authors:  Kimberly A Hofmeyer; Hyungjun Jeon; Xingxing Zang
Journal:  J Biomed Biotechnol       Date:  2011-09-25

Review 9.  Regulatory dendritic cells for immunotherapy in immunologic diseases.

Authors:  John R Gordon; Yanna Ma; Laura Churchman; Sara A Gordon; Wojciech Dawicki
Journal:  Front Immunol       Date:  2014-01-31       Impact factor: 7.561

Review 10.  Generation of Tolerogenic Dendritic Cells and Their Therapeutic Applications.

Authors:  Seungbo Yoo; Sang-Jun Ha
Journal:  Immune Netw       Date:  2016-02-25       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.